Abstract
Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Current Pharmaceutical Biotechnology
Title:Macrocyclic Lactones for Parasite Control in Equids
Volume: 13 Issue: 6
Author(s): E. T. Lyons and S. C. Tolliver
Affiliation:
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Abstract: Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Export Options
About this article
Cite this article as:
T. Lyons E. and C. Tolliver S., Macrocyclic Lactones for Parasite Control in Equids, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399310
DOI https://dx.doi.org/10.2174/138920112800399310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antinociceptive Effects of Aza-Bicyclic Isoxazoline-Acylhydrazone Derivatives
in Different Models of Nociception in Mice
Current Topics in Medicinal Chemistry Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Brain Hyperthermia During Physiological and Pathological Conditions: Causes, Mechanisms, and Functional Implications
Current Neurovascular Research Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke
Current Neurovascular Research Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure
Current Stem Cell Research & Therapy The Long-Term Effect of Medically Enhancing Melanin Intrinsic Bioenergetics Capacity in Prematurity
Current Genomics KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design